Zolpimist

Product manufactured by Aytu Bioscience, Inc.

Application Nr Approved Date Route Status External Links
NDA022196 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Zolpimist (zolpidem Tartrate) Is Indicated For The Short-Term Treatment Of Insomnia Characterized By Difficulties With Sleep Initiation. Zolpidem Tartrate Has Been Shown To Decrease Sleep Latency For Up To 35 Days In Controlled Clinical Studies [see Clinical Studies ( 14 )]. The Clinical Trials Performed In Support Of Efficacy Were 4-5 Weeks In Duration With The Final Formal Assessments Of Sleep Latency Performed At The End Of Treatment. Zolpimist Is Indicated For The Short-Term Treatment Of Insomnia Characterized By Difficulties With Sleep Initiation. Zolpidem Tartrate Has Been Shown To Decrease Sleep Latency For Up To 35 Days In Controlled Clinical Studies. ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Zolpidem Tartrate ZOLPIDEM TARTRATE ZINC3876

Comments